Ingredient news
PS Supplement Trial Reports Short-Term Memory Gains in MCI
By Nutranexa News |
A randomized placebo-controlled trial in Chinese older adults with mild cognitive impairment reported that a phosphatidylserine-containing supplement improved several cognitive measures, especially short-term memory.
What Was Tested
A paper indexed by PubMed in January 2025 examined a food supplement containing phosphatidylserine in Chinese older adults with mild cognitive impairment using a randomized, double-blind, placebo-controlled design.
This is a clinically focused setting, so the study matters more for technical evidence mapping than for direct consumer claim copying.
What the Paper Reported
The PubMed summary says the supplement could improve different cognitive functions in the MCI group, especially short-term memory.
The same summary notes increases in serum n-3 PUFAs and neurotransmitter levels, with serum ALA described as a possible mediator.
Buyer Takeaway
Ingredient buyers should separate a disease-population trial from general-market claim use, but the paper is still a useful signal on dose framing and co-ingredient design in cognition products.
Studies like this also reinforce the value of documenting exactly what was in the tested formula rather than treating 'PS' as a uniform evidence category.